EUVIMEDExplore EUVIMED
CrossrefInfo card

Guidelines on the Use of Therapeutic Apheresis in Clinical Practice—Evidence‐Based Approach From the Writing Committee of the American Society for Apheresis: The Tenth Special Issue

Nicole D. Zantek, Caroline R. Alquist, Jan C. Hofmann, Reinhard Klingel, Yosef Levenbrown, Oluwatoyosi A. Onwuemene, Gopal Patidar, Christopher J. Patriquin, Jay S. Raval, Amber P. Sanchez, Jennifer Schneiderman, Yvette C. Tanhehco, Laura Connelly‐Smith

Journal of Clinical Apheresis · 2026-09 · 41 (S2)

DOI: 10.1002/jca.70141 ↗
AbstractBibliographic details

Abstract

ABSTRACT The American Society for Apheresis (ASFA) Journal of Clinical Apheresis (JCA) Special Issue Writing Committee is charged with reviewing, updating, and categorizing indications for the evidence‐based use of therapeutic apheresis (TA) in human disease. As in recent editions, the Tenth Edition of the JCA Special Issue committee has incorporated systematic review and evidence‐based approaches in the grading of evidence and categorization of apheresis indications to make recommendations on the use of apheresis in a wide variety of diseases and conditions. This edition has largely maintained the general layout and concept of a fact sheet introduced in the Fourth Edition (2007). Each fact sheet succinctly summarizes the evidence for the use of TA in a specific disease entity or medical condition. The Tenth Edition comprises 93 fact sheets and 183 graded and categorized indications. This includes two new fact sheets and several changes to indications, categorization, or grade on existing fact sheets. The Tenth Edition of the JCA Special Issue seeks to continue to serve as a key resource that guides the utilization of TA in the treatment of human disease.

Knowledge that fits your work.

From a free start through personal literature research to the complete Research Suite.

View plans →

Are all publisher full texts included?

No. Bibliographic records, abstracts and full texts are different content types. Full-text availability depends on the source, open access and your existing licences. An EUVIMED plan does not replace additional publisher rights.

View plans →